Creo Medical Group PLC Director/PDMR Shareholding (0033N)

TIDMCREO

RNS Number : 0033N

Creo Medical Group PLC

27 May 2022

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Director/PDMR Shareholding

Chief Financial Officer purchases 70,000 shares; Non-Executive Chairman purchases 15,435 shares

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has received notification that Charles Spicer, Non-Executive Chairman of Creo, and Richard Rees, Chief Financial Officer, have purchased ordinary shares of GBP0.001 each in the Company ("Ordinary Shares").

Charles Spicer has purchased a total of 15,435 ordinary shares at a price of 97.18p per ordinary share. Following this transaction, Charles Spicer's total direct interest in the Company held via his Self-Invested Personal Pension ("SIPP") is now 143,411 ordinary shares, representing approximately 0.08% of the Company's issued share capital.

Richard Rees has purchased a total of 70,000 ordinary shares at a price of 96.75p per ordinary share; 21,400 of these shares are held via his SIPP. Richard Rees' total direct interest in the Company is now 73,615 ordinary shares, representing 0.04% of the Company's issued share capital.

Enquiries:

 
 Creo Medical Group plc                                                  www.creomedical.com 
 Richard Rees (CFO)                                                      [phone] 
 
 Cenkos Securities plc                                                   [phone] 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Numis Securities Limited (Joint 
  Broker) 
  Freddie Barnfield / James Black 
  / Duncan Monteith                                                      [phone] 
 
 Walbrook PR Ltd                           Tel: + 44 ( 0)20 7933 8780 or [e-mail] 
 Paul McManus / Sam Allen /                           Mob: [phone] 
  Phillip Marriage                                             558 258 / [phone] 
 

About Creo Medical

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                     Charles Spicer 
      ---------------------------------------  ------------------------------------------ 
 2     Reason for the notification 
      ----------------------------------------------------------------------------------- 
 a)    Position/status                          Non-Executive Chairman 
      ---------------------------------------  ------------------------------------------ 
 b)    Initial notification                     Initial notification 
        /Amendment 
      ---------------------------------------  ------------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------------- 
 a)    Name                                     Creo Medical Group plc 
      ---------------------------------------  ------------------------------------------ 
 b)    LEI                                      213800H188ZDCWWXFA21 
      ---------------------------------------  ------------------------------------------ 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ----------------------------------------------------------------------------------- 
 a)    Description of the                       Ordinary shares of GBP0.001 each 
        financial instrument, 
        type of instrument 
 
       Identification code                      GB00BZ1BLL44 
 
 b)    Nature of the transaction                Purchase of Ordinary Shares via SIPP 
      ---------------------------------------  ------------------------------------------ 
 c)    Price(s) and volume(s) 
                                                ------------------  ------------------- 
                                                 Price(s)            Volume(s) 
                                                ------------------  ------------------- 
                                                 97.18p              15,435 
                                                ------------------  ------------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                      N/A - single transaction 
 
  - Price 
 
 e)    Date of the transaction                  26 May 2022 
      ---------------------------------------  ------------------------------------------ 
 f)    Place of the transaction                 London Stock Exchange 
      ---------------------------------------  ------------------------------------------ 
 
 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                          Richard Rees 
      ----------------------------  -------------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------- 
 a)    Position/status               Chief Financial Officer 
      ----------------------------  -------------------------------------- 
 b)    Initial notification          Initial notification 
        /Amendment 
      ----------------------------  -------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------- 
 a)    Name                          Creo Medical Group plc 
      ----------------------------  -------------------------------------- 
 b)    LEI                           213800H188ZDCWWXFA21 
      ----------------------------  -------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------- 
 a)    Description of the            Ordinary shares of GBP0.001 each 
        financial instrument, 
        type of instrument 
 
       Identification code           GB00BZ1BLL44 
 
 b)    Nature of the transaction     Purchase of Ordinary Shares 
 
                                      Purchase of Ordinary Shares via SIPP 
      ----------------------------  -------------------------------------- 
 c)    Price(s) and volume(s)          Price(s)   Volume(s) 
                                        96.75p     48,600 
                                                  ---------- 
                                        96.75p     21,400 
                                                  ---------- 
      ----------------------------  -------------------------------------- 
 d)    Aggregated information 
 
  - Aggregated volume                70,000 
 
  - Price                            GBP67,725.00 
 
 e)    Date of the transaction       26 May 2022 
      ----------------------------  -------------------------------------- 
 f)    Place of the transaction      London Stock Exchange 
      ----------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFEAESIRFIF

(END) Dow Jones Newswires

May 27, 2022 02:01 ET (06:01 GMT)